Exxon Mobil Equity Method Investments increased by 3.2% to $33.71B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.9%, from $34.00B to $33.71B. Over 5 years (FY 2020 to FY 2025), Equity Method Investments shows relatively stable performance with a 1.9% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $31.23B | $34.52B | $34.08B | $34.01B | $34.00B | $32.66B | $32.68B | $32.65B | $33.71B |
| QoQ Change | — | +10.6% | -1.3% | -0.2% | -0.0% | -4.0% | +0.1% | -0.1% | +3.2% |
| YoY Change | — | +10.6% | -1.3% | -0.2% | — | — | — | -4.0% | -0.9% |
| Segment | Q4 '21 | Q4 '22 | Q4 '23 | Q4 '24 | Q4 '25 |
|---|---|---|---|---|---|
| Upstream | $0.71 | $0.71 | $0.71 | $0.50 | $0.50 |
| Corporate And Financing | -$337.00M | -$113.00M | -$120.00M | — | — |
| Total | $31.23B | $34.52B | $34.08B | $34.01B | $32.65B |
Corporate And Financing was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
| Segment | Q4 '22 | Q4 '23 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Non-U.S. | $26.25B | $26.27B | $25.77B | $25.75B | $24.22B | $24.06B | $23.87B | $24.77B |
| Total | $34.52B | $34.08B | $34.01B | $34.00B | $32.66B | $32.68B | $32.65B | $33.71B |